Endocrine Abstracts

Purpose: to assess the possibility of predicting the effectiveness of pharmacotherapy with metformin in patients with type 2 diabetes mellitus (DM2) depending on the single nucleotide polymorphism of the nitric oxide synthase gene.

Materials and methods: 186 patients were examined, referred for planned hospitalization, the duration of DM2 was 6-8 years, the target level of glycated hemoglobin was 7.5%, the actual level was 8.3%. All patients were prescribed metformin. Single nucleotide polymorphism of the gene (SNP) eNOS3 C786T (rs 2070744) was determined by real-time PSR, the level of Klotho protein was determined by ELISA, and the level of glycated hemoglobin was determined by BioRad. According to the results of the genetic study, the patients were divided into three groups: with the CC, TC and TT genotypes (SNP) eNOS3 C786T (rs 2070744).

Results: Patients with genotype CC achieved and maintained glycated hemoglobin levels below the target in 86% of cases when metformin was used at a dose of 1700 mg per day. In the same group, the Klotho protein level was significantly higher than in the other groups (P<0,05).

Conclusions: The use of metformin as monotherapy at a dose of 1700 mg/day may sometimes be sufficient in the presence of the CC genotype. The patients with TC and TT genotypes need to the combined hypoglycemic pharmacotherapy at the start.